Business
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Topline results anticipated fourth quarter of 2022 BRISBANE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"Topline results anticipated fourth quarter of 2022\nBRISBANE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of patient enrollment in the Phase 2b ORIGIN clinical trial of atacicept, the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). ORIGIN is a multinational dose-ranging study evaluating the efficacy and safety of atacicept in patients with IgA nephropathy (IgAN) who continue to have persistent proteinuria and remain at high risk of disease progression despite being on a stable prescribed regimen of renin-angiotensin-aldosterone system inhibition (RAASi) with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB). “We have been seeking a disease modifying therapy for IgAN to potentially slow or reverse disease progression,” said Richard Lafayette, M.D., FACP, Professor of Medicine, Director, Stanford Glomerular Disease Center, Stanford University School of Medicine, and a clinical investigator in the trial. “Recently, new data analysis from the Phase 2a JANUS clinical trial in patients with IgAN, showed atacicept is the first known investigational therapeutic to reduce IgG autoantibodies as well as its autoantigen, Gd-IgA1 – the source of immune complexes that cause disease. This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept. We look forward to the results of the ORIGIN trial which will be a first for the field.” “We are excited to complete enrollment in the Phase 2b ORIGIN trial and reach this significant milestone for atacicept as we work diligently amidst a global pandemic and geopolitical crises to provide a much-needed treatment option for patients with IgAN,” said Celia Lin, M.D., Chief Medical Officer at Vera Therapeutics. “IgAN represents a high unmet medical need in the world, with an estimated 400,000 patients in the U.S., the European Union, and Japan – up to half of whom will develop end-stage renal disease within 20 years from initial diagnosis, requiring dialysis or kidney transpla...